Back to top

oncology-screening: Archive

Zacks Equity Research

RXRX Q2 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down

Recursion Pharmaceuticals stock drops as Q2 loss widens and pipeline shake-up continues, despite revenues boost from Sanofi milestone.

CRMDPositive Net Change ARVNPositive Net Change IMCRPositive Net Change RXRXNegative Net Change

Zacks Equity Research

Recursion Pharmaceuticals to Report Q2 Earnings: What's in the Cards?

RXRX eyes Q2 earnings beat despite past misses, with a refocused pipeline and new data updates on key drug candidates.

ZTSNegative Net Change ACADPositive Net Change RXRXNegative Net Change